As a "triple G" or GLP-1, GIP, and GCG tri-agonist, Retatrutide stands out for its multifaceted approach
Research and clinical experience suggest that IV NAD+ produces a sharp but short-lived spike in plasma levels that does not reliably translate to intracellular increases, which is where the therapeutic effect actually happens
Tirzepatide is a dual agonist that activates both GIP and GLP-1 receptors, which is thought to explain its larger average weight loss in clinical trials
With over half of adults in Europe living with overweight or obesity, understanding who may benefit most from interventions that encourage adherence is essential to improving treatment use and subsequent health outcomes and quality of life. Limits of What the Data Reveals Despite the important findings, the authors acknowledge several limitations of the study, including the fact that anthropometric measures such as the exact BMI are not generally available in Danish health registries, and they could not assess individual-level income, insurance coverage, or out-of-pocket pay, which could partially affect the conclusions
, /
